QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
QQQ   419.93 (-0.82%)
AAPL   165.58 (-0.87%)
MSFT   402.29 (-0.49%)
META   490.73 (-2.21%)
GOOGL   155.13 (-0.56%)
AMZN   176.75 (-1.38%)
TSLA   150.09 (+0.11%)
NVDA   824.46 (-2.63%)
AMD   151.82 (-2.10%)
NIO   3.86 (-3.50%)
BABA   68.77 (-0.16%)
T   16.33 (+0.00%)
F   12.13 (+0.58%)
MU   109.43 (-2.23%)
GE   151.44 (-0.98%)
CGC   7.69 (-1.79%)
DIS   111.90 (-0.47%)
AMC   3.14 (+7.53%)
PFE   25.62 (+0.91%)
PYPL   62.21 (+0.18%)
XOM   120.34 (+1.54%)
NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

$19.27
+0.07 (+0.36%)
(As of 10:47 AM ET)
Today's Range
$19.11
$19.54
50-Day Range
$18.86
$26.52
52-Week Range
$18.61
$30.52
Volume
101,462 shs
Average Volume
622,049 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

Veracyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
49.9% Upside
$29.00 Price Target
Short Interest
Bearish
4.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.02
Upright™ Environmental Score
News Sentiment
0.38mentions of Veracyte in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$216,500 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.29) to $0.01 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.57 out of 5 stars

Medical Sector

253rd out of 918 stocks

Medical Laboratories Industry

9th out of 20 stocks

VCYT stock logo

About Veracyte Stock (NASDAQ:VCYT)

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Stock Price History

VCYT Stock News Headlines

Veracyte, Inc. (VCYT)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Veracyte (NASDAQ:VCYT) Hits New 1-Year Low on Analyst Downgrade
Veracyte, Inc. (NASDAQ:VCYT) Short Interest Up 32.8% in March
Veracyte (NASDAQ:VCYT) Shares Gap Down to $21.43
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
What Makes Veracyte (VCYT) a Lucrative Investment?
VCYT Apr 2024 30.000 call
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Recap: Veracyte Q4 Earnings
VCYT Mar 2024 35.000 put
VCYT Mar 2024 20.000 put
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/19/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:VCYT
Employees
815
Year Founded
2006

Price Target and Rating

Average Stock Price Target
$29.00
High Stock Price Target
$34.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+50.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-74,400,000.00
Pretax Margin
-21.22%

Debt

Sales & Book Value

Annual Sales
$361.05 million
Cash Flow
$0.09 per share
Book Value
$14.30 per share

Miscellaneous

Free Float
73,116,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
1.62

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 54)
    CEO & Director
    Comp: $1.25M
  • Ms. Rebecca ChambersMs. Rebecca Chambers (Age 45)
    Executive VP & CFO
    Comp: $772.41k
  • Ms. Annie McGuire (Age 43)
    Executive VP, General Counsel & Chief People Officer
    Comp: $633.65k
  • Mr. Jonathan Wygant (Age 53)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Senior VP & Chief Information Officer
  • Dr. Phillip G. Febbo M.D. (Age 58)
    Chief Scientific & Medical Officer
  • Ms. Karen Possemato
    Senior Vice President of Corporate Marketing, Communications & Commercial Operations
  • Mr. Robert Brainin (Age 53)
    Executive VP & Chief Business Officer
  • Dr. John Leite Ph.D.
    Chief Commercial Officer for CLIA Business
  • Ms. Corinne Danan
    Senior Vice President

VCYT Stock Analysis - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price target for 2024?

5 brokers have issued 1-year target prices for Veracyte's stock. Their VCYT share price targets range from $21.00 to $34.00. On average, they expect the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 49.9% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2024?

Veracyte's stock was trading at $27.51 on January 1st, 2024. Since then, VCYT stock has decreased by 29.7% and is now trading at $19.35.
View the best growth stocks for 2024 here
.

Are investors shorting Veracyte?

Veracyte saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average trading volume of 633,600 shares, the short-interest ratio is presently 5.7 days.
View Veracyte's Short Interest
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $98.20 million for the quarter, compared to analysts' expectations of $95.49 million. Veracyte had a negative net margin of 20.61% and a negative trailing twelve-month return on equity of 2.02%.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $394.0 million-$402.0 million, compared to the consensus revenue estimate of $393.3 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.46%), Diversified Trust Co (0.03%), Los Angeles Capital Management LLC (0.03%), Artemis Investment Management LLP (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
This page (NASDAQ:VCYT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners